Clinical Trial Update: Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant trastuzumab, pyrotinib plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer; status unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fudan University | Conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN